Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.03 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | reachable by antibody | 0.45 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 1 Parkinson's papers of 72 | 0.91 |
| pathways Reactome | 2 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 6319
Sealed predictions
- APEH in dopamine neurons, braak+0.26 (p 0.498) → -0.16 (p 0.685)receipt 6328
Swarm cases
receipt 6328: APEH in dopamine neurons, braak
- power
- full sample +0.05 (p 0.854, n 18), 95% CI -0.43 to +0.50. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: +0.03 (p 0.901, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.09 (p 0.722, n 18). could be the mix.
- skeptic
- leave-one-out range -0.08 to +0.16, sign flips 3; without severely affected donors +0.05 (p 0.854, n 18). fragile.
- cell type
- strongest in OPCs: -0.70 (p 0.0012, n 18) vs +0.05 in dopamine neurons. proposing OPCs.
- axis
- no measure beats "tracks Braak Lewy-body stage" for APEH in dopamine neurons.
follow-up registered; not confirmed in substantia nigra, an independent cohort.
follow-up APEH · OPCs · braak: substantia nigra, an independent cohort (Parkinson's or LBD vs controls) -0.68 p 0.016 (needs p < 3.2e-4)
Receipts
loading the receipts